Acumen Pharmaceuticals, Inc.
ABOS
$0.05
Change (1 day)
$5.09
Year High
$1.72
Year Low
Categories
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
P/E ratio for Acumen Pharmaceuticals, Inc. (ABOS)
P/E ratio as of 2023: -3.56
According to Acumen Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.56. At the end of 2022 the company had a P/E ratio of -5.42.
P/E ratio history for Acumen Pharmaceuticals, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.56 |
| 2022 | -5.42 |
| 2021 | -1.51 |
| 2020 | -110.19 |
| 2019 | -102.65 |